TCTMD round table
Jonathan Hill, MD, FRCP is director of the Cardiac Catheterization Laboratories at King’s College Hospital. His primary focus is on complex interventional procedures especially chronic total occlusion and percutaneous left ventricular support. At King’s he has developed an active clinical research programme using optical coherence tomography and is a strong advocate for a universal intravascular imaging approach to guide percutaneous intervention. He is a graduate of Cambridge and Edinburgh Universities, graduating in 1992. He trained in cardiology at The London Chest and St. Bartholomew’s Hospitals. In 1999 he was awarded the first National Heart Lung and Blood Institute Bench to Bedside award and trained in basic science and interventional research within the Cardiovascular Branch of the National Institutes of Health in Bethesda. He undertook a research program relating to stem and progenitor cells in cardiovascular disease with a particular interest in vascular repair. He completed his interventional cardiology training at the London Chest Hospital. In 2005, he was appointed as Clinical Senior Lecturer and Consultant Cardiologist at King’s College London. He is a member of the steering committee of the Illumien IV trial.
Dr. Gregg W. Stone, M.D., FACC, FSCAI serves as a Vice President and the Director of Cardiovascular Research and Education at the Cardiovascular Research Foundation. Dr. Stone serves as the Director of Cardiovascular Research and Education at the Columbia University Medical Center/New York-Presbyterian Hospital in New York. He served as a Member of Scientific Advisory Board at XTENT, Inc. He co-founder of Clinsights, Inc. Dr. Stone practices interventional cardiology at Lenox Hill Hospital in New York and has performed over 5,000 angioplasty and stent procedures. He serves as a Medical Venture Partner, Advisor and Member of Scientific Advisory Board at BioStar Ventures. He is an internationally recognized cardiologist who has led over 40 trials and has served as the national or international principle investigator for more than 25 multicenter randomized clinical trials. Dr. Stone served as Medical Advisor of InfraReDx, Inc. His areas of expertise include interventional therapies of acute coronary syndromes and myocardial infarction; adjunct pharmacology; new device angioplasty including distal embolic protection, thrombectomy, vascular brachytherapy and stent grafts; intravascular ultrasound imaging; and drug eluting stents. Dr. Stone has particular expertise in drug-eluting stents, vulnerable plaque, antithrombotic and antiplatelet agents, contrast nephropathy, transcatheter valve therapies and new device development. His medical practice is devoted to interventional cardiology and he has performed more than 5000 angioplasty and stent procedures. He held similar positions at the Washington Hospital Center in Washington, D.C. He served as a Scientific Advisor at Ascent BioMedical Ventures. He served as the Director of Interventional Cardiology at the Cardiovascular Institute at Stanford University Medical Center and El Camino Hospital in California. Dr. Stone serves as Chairman of Scientific Advisory Board at Thermocore Medical Ltd. He serves as a Member of Advisory Board at InspireMD, Inc. He serves as a Member of Scientific Advisory Board at Medtronic CoreValve LLC, REVA Medical, Inc. and Ovalum Ltd. He has been a Member of Scientific Advisory Board at Ablative Solutions, Inc, since December 2,2015. He serves as a Member of Medical Advisory Board at Osprey Medical Inc. and Caliber Therapeutics, Inc. Dr. Stone serves as a Member of Scientific Advisory Board at MediGuide Ltd and Conor Medsystems, LLC. He serves as Member of Advisory Board of InspireMD, Inc. He serves as a Member of Scientific Advisory Council at Miracor Medical Systems GmbH. He has been a Director of Devax, Inc. since June 2003. He serves as the Director of Transcatheter Cardiovascular Therapeutics (TCT) and directs the National Interventional Cardiology Fellow's Course. He served as a Director of EndoSonics Corporation since February 1999. He served as a Director of Clinsights, Inc. He served as a Member of Scientific Advisory Board at Radiant Medical, Inc. and at Prescient Medical, Inc. Dr. Stone has served as the National or International Principle investigator for more than a dozen multicenter randomized trials, has authored more than 500 book chapters, manuscripts and abstracts published in the peer-reviewed literature and has delivered more than 1000 invited lectures around the world. He is triple board certified in Interventional Cardiology, Cardiovascular Disease and Internal Medicine. He is Professor of Medicine at Columbia University Medical Center and was chairman of the Cardiovascular Research Foundation in New York. Dr. Stone has extensive experience in advancing new innovative technologies through clinical research. He completed his general cardiology fellowship at Cedars-Sinai Medical Center in Los Angeles, C.A. and subsequently a dedicated fellowship in advanced coronary angioplasty in Kansas City, M.O. He also holds F.A.C.P. and F.A.C.C. degrees. Dr. Stone completed medical school at Johns Hopkins University Medical Center, in Baltimore, M.D., and his internship and residency at the New York Hospital-Cornell Medical Center in New York City.
Dr. Ali is Assistant Professor of Medicine at Columbia University Medical Center where he serves as the Director of Intravascular Imaging and Physiology and Director of the Cardio-renal program. He is also the Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation. Dr. Ali is the Global PI of the International Multicenter Randomized Controlled Trials ILUMIEN III and IV. Dr. Ali pioneered techniques to perform diagnostic angiography with ultra-low contrast volumes and performed interventions without contrast administration, protecting patients with advanced kidney disease from the need for dialysis.
2020 All rights reserved